- Home
- SMSI vs BLRX Comparison
SMSI vs BLRX Comparison
Compare SMSI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMSI
- BLRX
- Stock Information
- Founded
- SMSI 1982
- BLRX 2003
- Country
- SMSI United States
- BLRX Israel
- Employees
- SMSI N/A
- BLRX N/A
- Industry
- SMSI Computer Software: Prepackaged Software
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SMSI Technology
- BLRX Health Care
- Exchange
- SMSI Nasdaq
- BLRX Nasdaq
- Market Cap
- SMSI 15.3M
- BLRX 17.1M
- IPO Year
- SMSI 1995
- BLRX 2011
- Fundamental
- Price
- SMSI $0.59
- BLRX $3.22
- Analyst Decision
- SMSI Strong Buy
- BLRX Strong Buy
- Analyst Count
- SMSI 1
- BLRX 2
- Target Price
- SMSI $5.00
- BLRX $19.00
- AVG Volume (30 Days)
- SMSI 212.5K
- BLRX 24.0K
- Earning Date
- SMSI 11-05-2025
- BLRX 11-24-2025
- Dividend Yield
- SMSI N/A
- BLRX N/A
- EPS Growth
- SMSI N/A
- BLRX N/A
- EPS
- SMSI N/A
- BLRX N/A
- Revenue
- SMSI $18,359,000.00
- BLRX $17,251,000.00
- Revenue This Year
- SMSI N/A
- BLRX N/A
- Revenue Next Year
- SMSI $46.15
- BLRX N/A
- P/E Ratio
- SMSI N/A
- BLRX N/A
- Revenue Growth
- SMSI N/A
- BLRX 1.19
- 52 Week Low
- SMSI $0.57
- BLRX $2.30
- 52 Week High
- SMSI $1.95
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- SMSI 36.84
- BLRX 39.65
- Support Level
- SMSI $0.58
- BLRX $3.23
- Resistance Level
- SMSI $0.65
- BLRX $3.50
- Average True Range (ATR)
- SMSI 0.05
- BLRX 0.21
- MACD
- SMSI -0.01
- BLRX -0.01
- Stochastic Oscillator
- SMSI 12.47
- BLRX 20.00
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.